National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

capecitabinePatient Information
A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites. As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells. FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Xeloda
Abbreviation:CAPE
Code name:Ro 09-1978/000
Chemical structure name:5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine



Previous:Cancidas, candesartan cilexetil, canertinib dihydrochloride, cannabis-based oromucosal spray GW-1000-02, Canvaxin
Next:Capoten, captopril, caracemide, carbamazepine, carbogen

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov